Search Results - daniel+judge

2 Results Sort By:
Preventing Myocardial Loss and Sudden Death in Patients with Arrhythmogenic Cardiomyopathy via Rescuing of AIF/thioredoxin-2 Signaling
Unmet NeedAbout 400,000 to 460,000 people die each year from sudden cardiac death (SCD). Patients with Arrhythmogenic Cardiomyopathy (ACM) are at increased risk for heart failure and SCD triggered by exercise. Common ACM driver mutations occur in about 1 out of every 10,000 people. However, the physiological mechanisms that drive myocardial loss and...
Published: 6/27/2024   |   Inventor(s): Stephen Chelko, Nazareno Paolocci, Gizem Keceli, Daniel Judge, Nunzianna Doti, Menotti Ruvo, Alessandra Monti, Nuria Amat, Peter Andersen
Keywords(s): Cardiac Arrest, Cardiovascular Diseases, Disease Indication, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations > Cardiovascular > Cardiac Arrest, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules
TGFbeta Antagonists, Including AT1 Receptor Blockers, Rescue the Multisystem Pathogenesis of Marfan Syndrome
Unmet Need: Marfan syndrome is a disorder of the body's connective tissues. One out of every 5,000 people in the world has Marfan syndrome, or a related connective tissue disorder. Features of the disease include, emphysema (which frequently results in spontaneous lung rupture), eye problems, skeletal abnormalities, heart valve and aortic problems...
Published: 6/27/2024   |   Inventor(s): Enid Neptune, Jennifer Habashi, Daniel Judge, Ronald Cohn, Harry Dietz
Keywords(s): Antibodies, Biologics, Disease Indication, Emphysema, Lung Disorders, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases > Emphysema, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Respiratory Diseases, Technology Classifications > Therapeutic Modalities
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum